Elife logo

編集者

目次

    更新日: 2024.10.03
    Medical information: Suglat, Forxiga, Canaglu, Lusefi

    Important safety information including dosage, side effects, and precautions of SGLT2 inhibitors.

    Image assets%2Ff84ab7e7f0af4058b5c5065e08214eae%2Fded6bc3d99c44944ab220f418e220c9b

    Dosage & Administration

    ・Take 1 tablet once a day, before or after breakfast, with a glass of water.


    ・If you miss a dose, take the missed dose as soon as possible. However, if there is less than 12 hours until the next dose, skip the missed one and wait until your next scheduled dose.


    ・Do not take more than 1 tablet per day.

    Side Effects

    ・Reported side effects include frequent urination, constipation, dry mouth, urinary tract infections, and hypoglycemia*1. However, most individuals can take this medication without any problems.


    ・If you experience any serious side effects, stop taking the medication and consult your nearest medical facility immediately.


    *1: Symptoms of hypoglycemia include weakness, fatigue, intense hunger, cold sweats, pallor, palpitations, tremors, headache, dizziness, nausea, and visual changes.

    Precautions

    ・Do not take this medication if you have kidney or liver dysfunction, are pregnant, planning to become pregnant, breastfeeding, or within 3 months postpartum.


    ・Drink at least 500 ml more water than usual and stay hydrated regularly.


    ・Avoid alcohol as it can increase the risk of hypoglycemia.

    Approval status in Japan

    ・Suglat

    It is approved by the Ministry of Health, Labour and Welfare for the treatment of type 2 and type 1 diabetes.


    Prescription for other purposes such as obesity treatment is not approved in Japan.


    ・Forxiga

    It is approved by the Ministry of Health, Labour and Welfare for the treatment of type 2 diabetes, type 1 diabetes and chronic kidney disease.


    Prescription for other purposes such as obesity treatment is not approved in Japan.


    ・Canaglu

    It is approved by the Ministry of Health, Labour and Welfare for the treatment of type 2 diabetes mellitus and chronic kidney disease complicated by type 2 diabetes mellitus.


    Prescription for other purposes such as obesity treatment is not approved in Japan.


    ・Lusefi

    It is approved by the Ministry of Health, Labour and Welfare for the treatment of type 2 diabetes.


    Prescription for other purposes such as obesity treatment is not approved in Japan.


    *Medicines prescribed in this department are not covered by the Adverse Reactions Relief System.

    Availability of approved medicines that have the same active ingredients in Japan

    ・There are no domestically approved drugs that have the same active ingredient as the above SGLT2 inhibitors and meet weight loss use.

    Means of acquisition

    ・Our affiliated clinic physicians purchase SGLT2 inhibitors through a domestic pharmaceutical distributor.